The Belgian Health Care Knowledge Center (KCE) is conducting research towards a faster, substantiated decision on the reimbursement of innovative medical products. The project started in 2019 and is still being conducted. In Belgium, innovative medical products become accessible to patients when they receive reimbursement from the Belgian health insurance (INAMI-RIZIV). After the manufacturer submits the application to the competent INAMI-committee, a lot of uncertainties appear regarding the effectiveness/cost-effectiveness of these products and their potential budget impact. In a case of lack of evidence, the innovative product will not be reimbursed. In order to make the evidence more available for the manufacturer, KCE is conducting research, which examines recent reimbursement files for innovative medicines and medical devices. The strengths and weaknesses of this evidence, which have already been identified by the INAMI committee, will be analyzed.
The final report on the solutions made by KCE will be based on the analysis of information collected by the INAMI committee involving various stakeholders. The details on the timelines of the research are not available.
The full details can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services “HTA Alerts” and “Reimbursement Alerts” every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).